<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Warfarin | Management | Anticoagulation - oral  | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers prescribing and management information for adults receiving warfarin for use within its licensed indication."/><meta data-react-helmet="true" property="og:description" content="Covers prescribing and management information for adults receiving warfarin for use within its licensed indication."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/anticoagulation-oral/management/warfarin/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Warfarin | Management | Anticoagulation - oral  | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/anticoagulation-oral/management/warfarin/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Anticoagulation - oral </a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Warfarin</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/anticoagulation-oral/","name":"Anticoagulation - oral "}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/anticoagulation-oral/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Warfarin"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Anticoagulation - oral : </span><span>Scenario: Warfarin</span></h1><p class="page-header__lead"><span>January 2021</span></p></div><p class="visually-hidden">Covers prescribing and management information for adults receiving warfarin for use within its licensed indication.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Anticoagulation - oral  chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Apixaban"><a aria-current="false" href="../apixaban/index.html"><span class="stacked-nav__content-wrapper">Scenario: Apixaban</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Dabigatran"><a aria-current="false" href="../dabigatran/index.html"><span class="stacked-nav__content-wrapper">Scenario: Dabigatran</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Edoxaban"><a aria-current="false" href="../edoxaban/index.html"><span class="stacked-nav__content-wrapper">Scenario: Edoxaban</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Rivaroxaban"><a aria-current="false" href="../rivaroxaban/index.html"><span class="stacked-nav__content-wrapper">Scenario: Rivaroxaban</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Warfarin"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Warfarin</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#starting-warfarin-treatment">Starting warfarin treatment</a><ol aria-label="Sections within Starting warfarin treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-bca">Basis for recommendation</a></li></ol></li><li><a href="index.html#duration-of-treatment">Duration of treatment</a><ol aria-label="Sections within Duration of treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-889">Basis for recommendation</a></li></ol></li><li><a href="index.html#contraindications-cautions">Contraindications and cautions</a><ol aria-label="Sections within Contraindications and cautions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-af8">Basis for recommendation</a></li></ol></li><li><a href="index.html#adverse-effects">Adverse effects</a><ol aria-label="Sections within Adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-949">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-96c">Basis for recommendation</a></li></ol></li><li><a href="index.html#surgery-dental-treatment">Surgery and dental treatment</a><ol aria-label="Sections within Surgery and dental treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-342">Basis for recommendation</a></li></ol></li><li><a href="index.html#monitoring">Monitoring</a><ol aria-label="Sections within Monitoring" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-96c">Basis for recommendation</a></li></ol></li><li><a href="index.html#monitoring-during-the-covid-19-pandemic">Monitoring during the Covid-19 pandemic</a><ol aria-label="Sections within Monitoring during the Covid-19 pandemic" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-8d9">Basis for recommendation</a></li></ol></li><li><a href="index.html#target-inrs">Target INRs</a><ol aria-label="Sections within Target INRs" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-935">Basis for recommendation</a></li></ol></li><li><a href="index.html#inr-not-in-range">INR not in range</a><ol aria-label="Sections within INR not in range" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-33a">Basis for recommendation</a></li></ol></li><li><a href="index.html#advice-to-patients">Advice to patients</a><ol aria-label="Sections within Advice to patients" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-08c">Basis for recommendation</a></li></ol></li><li><a href="index.html#self-testing-self-management">Self-testing and self-management</a><ol aria-label="Sections within Self-testing and self-management" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#suitability-for-self-testing-self-management">Suitability for self-testing and self-management</a></li><li class=""><a href="index.html#training-for-self-testing-self-management">Training for self-testing and self-management</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-571">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="warfarin" class="ChapterBody-module--wrapper--2HCfk "><h2 id="warfarin" class="visually-hidden">Scenario: Warfarin</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7a88d045-dc57-4995-ba18-f89ecf339219 --><!-- begin field 2a18ec48-6852-48f8-8367-acd900add83b --><p>From age 16 years onwards.</p><!-- end field 2a18ec48-6852-48f8-8367-acd900add83b --><!-- end item 7a88d045-dc57-4995-ba18-f89ecf339219 --></div><section aria-labelledby="starting-warfarin-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="starting-warfarin-treatment">What is the starting dose when warfarin treatment is initiated?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d41cf105-7ca2-4f58-a101-36305c05e6e6 --><!-- begin field 556c1b16-cd4b-4110-bdd3-deeeb91b3d82 --><ul><li><strong>Baseline prothrombin measurements should be taken before starting treatment with warfarin.</strong><ul><li><strong>The typical induction dose of warfarin </strong>is 10 mg daily for 2 days, but this should be tailored to individual requirements. <ul><li>A low starting dose (5 mg) is often more suitable for frail or elderly people, people with a low body weight, people with liver disease or cardiac failure, and people at high risk of bleeding. </li><li>Subsequent doses depend on the prothrombin time, reported as an international normalized ratio (INR). </li></ul></li><li><strong>The daily maintenance dose of warfarin</strong> is usually 3–9 mg, taken at the same time each day.<ul><li>The exact maintenance dose is dependent on the INR or other appropriate coagulation tests. Once the maintenance dose is stabilized in the therapeutic range, it is rarely necessary to alter it.</li></ul></li><li><strong>Where an immediate effect is required</strong> (for example in deep venous thrombosis or a pulmonary embolism), heparin or a low molecular weight heparin is given concurrently — this is done in secondary care. </li><li> <strong>Where there is less urgency </strong>(as in people disposed to or at special risk of thromboembolism), anticoagulant treatment may be initiated with warfarin alone.<ul><li><strong>For people with atrial fibrillation, </strong>there is no need to achieve anticoagulation rapidly; a slow-loading regimen is safe and achieves therapeutic anticoagulation in most people within 3–4 weeks. Warfarin 1 mg or 2 mg daily is generally an acceptable starting dose. The average daily maintenance dose is usually around 5 mg daily; however, there is wide variation, and the daily dose may be between 1–15 mg for some people.</li></ul></li><li><strong>Specialist advice should be sought if the person has a prolonged baseline prothrombin time.</strong><ul><li>Monitoring the person's INR may be problematic, and an alternative anticoagulant may be required. </li></ul></li></ul></li></ul><!-- end field 556c1b16-cd4b-4110-bdd3-deeeb91b3d82 --><!-- end item d41cf105-7ca2-4f58-a101-36305c05e6e6 --></div><section aria-labelledby="basis-for-recommendation-bca" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-bca">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bcaa1626-71c4-4d59-bd9b-cd3ca7cd4ac3 --><!-- begin field 7b8a45a7-cd3f-439c-8426-906b21942694 --><p>These recommendations are based on the British Committee for Standards in Haematology (BCSH) <em>Guidelines on oral anticoagulation with warfarin - fourth edition </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Antithrombotics: indications and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>], a Cochrane systematic review [<a class="bibliography-reference internal-reference" href="../../references/index.html">Garcia, 2016</a>], the Summary of Product Characteristics (SPC) for warfarin sodium 1 mg/1 ml oral suspension [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020f</a>], and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><h5>Initial dose of warfarin</h5><ul><li>There is no evidence to suggest that a 10 mg loading dose of warfarin is better than a 5 mg loading dose in people with acute thrombosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Garcia, 2016</a>]. However, the target international normalized ratio (INR) is achieved more rapidly if a 10 mg dose of warfarin is used on day one compared with a 5 mg dose [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Garcia, 2016</a>].</li><li>Heparin is administered concurrently with warfarin to provide immediate anticoagulation as it takes several days for warfarin to take effect, even with a loading dose [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>].</li></ul><!-- end field 7b8a45a7-cd3f-439c-8426-906b21942694 --><!-- end item bcaa1626-71c4-4d59-bd9b-cd3ca7cd4ac3 --></div></section></section><section aria-labelledby="duration-of-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="duration-of-treatment">What is the duration of treatment with warfarin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 26ba97e6-5829-48b8-865f-7fff0e3fa12b --><!-- begin field a3ed6add-b3e9-4f28-ac98-0d0160bcd643 --><ul><li><strong>For people with deep vein thrombosis (DVT) and pulmonary embolism (PE):</strong><ul><li>Duration of treatment will vary for each person, depending on a variety of factors. Experts are not unanimous on the optimal duration of warfarin treatment, but usually it should be continued for <em>at least</em>:<ul><li>Six weeks in people with distal DVT (calf vein thrombosis).</li><li>Three months in people with proximal DVT or PE where there are known temporary risk factors <em>and </em>there is considered to be a low risk of recurrence.</li><li>Six months in people with proximal DVT due to an unknown cause (idiopathic).</li><li>Long term if there have been recurrent DVTs or PEs.</li></ul></li><li>Warfarin can be stopped abruptly without harm when the duration of treatment is completed.</li></ul></li><li><strong>For people with atrial fibrillation (AF):</strong><ul><li>Warfarin treatment is usually long term.</li><li>If the person is going to have cardioversion, the target international normalized ratio (INR) should be achieved at least 3 weeks before cardioversion and 4 weeks after (if normal sinus rhythm is maintained).</li><li>People who have undergone cardioversion and have a high risk of AF recurring also require long-term warfarin treatment. People at high risk of AF recurring include those with:<ul><li>A history of failed attempts at cardioversion.</li><li>Structural heart disease (mitral valve disease, left ventricular dysfunction, or an enlarged left atrium).</li><li>A prolonged history of AF (greater than 12 months).</li><li>Previous recurrences of AF.</li></ul></li></ul></li><li><strong>For people with mechanical prosthetic heart valves,</strong> warfarin treatment is usually long term.</li></ul><!-- end field a3ed6add-b3e9-4f28-ac98-0d0160bcd643 --><!-- end item 26ba97e6-5829-48b8-865f-7fff0e3fa12b --></div><section aria-labelledby="basis-for-recommendation-889" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-889">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 889f1046-9847-4a6b-ac29-098ce85bb51b --><!-- begin field ec359cca-ff8e-49bf-8f9f-704f34a490a9 --><p>These recommendations are based on the British Committee for Standards in Haematology (BCSH) <em>Guidelines on oral anticoagulation with warfarin - fourth edition, </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Antithrombotics: indications and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>], and the National Institute for Health and Clinical Excellence (NICE) guideline <em>Atrial fibrillation: the management of atrial fibrillation </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014b</a>].</p><!-- end field ec359cca-ff8e-49bf-8f9f-704f34a490a9 --><!-- end item 889f1046-9847-4a6b-ac29-098ce85bb51b --></div></section></section><section aria-labelledby="contraindications-cautions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="contraindications-cautions">What are the contraindications and cautions for warfarin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item bbee7b53-2069-4e80-b422-b5388d019384 --><!-- begin field 94e42a28-5009-477b-a0d0-d23e8a92c69c --><ul style="margin-top: 0cm;" type="disc"><li class="MsoNormal" style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><strong>Warfarin is contraindicated:</strong></li><ul style="margin-top: 0cm;" type="circle"><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">In people with:</li><ul style="margin-top: 0cm;" type="square"><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Haemorrhagic stroke.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Clinically significant bleeding. </li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Severe hepatic impairment.</li></ul><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Within 72 hours of major surgery with risk of severe bleeding.</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Within 48 hours postpartum.</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">In pregnant women — due to the risk of teratogenicity.</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">In people taking drugs where <a class="topic-reference internal-reference" href="index.html#drug-interactions">interactions</a> lead to a significantly increased risk of bleeding.</li></ul><li class="MsoNormal" style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><strong>Warfarin should be used with caution in the following groups: </strong></li><ul style="margin-top: 0cm;" type="circle"><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Elderly people.</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">People with increased risk of bleeding — warfarin should be used with extreme caution if the benefit of anticoagulation outweighs the risk. Risk factors for bleeding include:</li><ul style="margin-top: 0cm;" type="square"><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">History of gastrointestinal bleeding.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">History of peptic ulceration.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Recent ischaemic stroke.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Uncontrolled hypertension.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Concurrent nonsteroidal anti-inflammatory (NSAID) use.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Recent surgery.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">The postpartum period — should be delayed until risk of bleeding is low, usually 5–7 days after delivery. </li></ul><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">People with:</li><ul style="margin-top: 0cm;" type="square"><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Thrombophilia — warfarin should be introduced slowly due to the risk of skin necrosis.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Thyroid disorders — the rate of warfarin metabolism depends on thyroid status. People with hyperthyroidism or hypothyroidism should be closely monitored.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Risk factors for over coagulation, such as severe hypertension, or severe renal or hepatic impairment — international normalized ratio (INR) should be monitored more frequently.</li><li class="MsoNormal" style="mso-list: l0 level3 lfo1; tab-stops: list 108.0pt;">Mild to moderate hepatic or renal impairment.</li></ul></ul><li class="MsoNormal" style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><strong>The following factors may exaggerate the effect of warfarin and necessitate a dose reduction:</strong></li><ul style="margin-top: 0cm;" type="circle"><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Weight loss.</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Acute illness</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Smoking cessation.</li></ul><li class="MsoNormal" style="mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><strong>The following factors may reduce the effect of warfarin and<strong> necessitate a dose </strong>increase:</strong></li><ul style="margin-top: 0cm;" type="circle"><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Weight gain.</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Diarrhoea.</li><li class="MsoNormal" style="mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;">Vomiting.</li></ul></ul><!-- end field 94e42a28-5009-477b-a0d0-d23e8a92c69c --><!-- end item bbee7b53-2069-4e80-b422-b5388d019384 --></div><section aria-labelledby="basis-for-recommendation-af8" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-af8">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item af883dee-068e-44d1-bd9c-92360b0930ea --><!-- begin field 7daa0bc5-79c9-43cb-bd06-7e0ee9d67620 --><p>These recommendations are based on the Summary of Product Characteristics (SPC) for warfarin sodium 1 mg/1 ml oral suspension [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020f</a>] and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field 7daa0bc5-79c9-43cb-bd06-7e0ee9d67620 --><!-- end item af883dee-068e-44d1-bd9c-92360b0930ea --></div></section></section><section aria-labelledby="adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="adverse-effects">What are the adverse effects of warfarin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 086cd5cd-6e2f-4d24-86a4-9917d08078fd --><!-- begin field f0a38dbe-fd0b-411b-b1b5-f8f676af2b15 --><ul><li><strong>Bleeding is a common adverse effect of all anticoagulants, including warfarin, and it can occur in any part of the body.</strong><br><ul><li>Advise the person taking warfarin to seek immediate medical advice if:<ul><li>Spontaneous bleeding occurs whilst on warfarin and the bleeding does not stop, or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, coughing up blood, a subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li>They get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li></ul></li><li> Vitamin K1 (phytomenadione) is indicated as an antidote to coumarin anticoagulants (such as warfarin) in the treatment of haemorrhage or threatened haemorrhage, associated with a low blood level of prothrombin or factor VII.</li></ul></li><li><strong>Other adverse effects of warfarin include:</strong><ul><li>Rare or very rare — alopecia, nausea, and vomiting.</li><li>Frequency unknown — blue toe syndrome, diarrhoea, fever, haemothorax, jaundice, pancreatitis, skin reactions, and abnormal hepatic function. </li></ul></li><li><strong>Skin necrosis and calciphylaxis are rare but serious adverse effects of warfarin.</strong><ul><li>Warfarin-related skin necrosis presents as painful, localized skin lesions (due to thrombosis of venules and capillaries) within subcutaneous fat.<ul><li>It is more likely in people with acute heparin-induced thrombocytopenia (HIT) or in people with pre-existing congenital protein C or protein S deficiency.</li><li>The lesions can occur in areas of fatty tissue, such as the breasts, abdomen, or in the extremities.</li><li>Treatment with warfarin should be stopped if warfarin-related skin necrosis is suspected.</li></ul></li><li>Calciphylaxis is a rare syndrome of vascular calcification with cutaneous necrosis, associated with high mortality.<ul><li>It mainly occurs in people with end-stage renal disease on dialysis or in people with known risk factors, such as protein C or S deficiency, hyperphosphataemia, hypercalcaemia, or hypoalbuminaemia.</li><li>Rare cases of calciphylaxis have been reported in people taking warfarin, also in the absence of renal disease.</li><li>Advise people taking warfarin to seek urgent medical advice if they develop a painful skin rash.</li><li>If diagnosed, appropriate treatment should be started and stopping warfarin treatment considered.</li></ul></li></ul></li></ul><!-- end field f0a38dbe-fd0b-411b-b1b5-f8f676af2b15 --><!-- end item 086cd5cd-6e2f-4d24-86a4-9917d08078fd --></div><section aria-labelledby="basis-for-recommendation-949" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-949">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 94908287-4a7d-4a66-9192-af3302c03f37 --><!-- begin field 821946e9-ba9d-46e8-845d-2b063aa6e8b1 --><p>These recommendations are based on the Summary of Product Characteristics (SPC) for warfarin sodium 1 mg/1 ml oral suspension [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020f</a>], the SPC for Konakion® MM 10 mg/ml [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020j</a>], the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>], and the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Warfarin - reports of calciphylaxis</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016a</a>].</p><!-- end field 821946e9-ba9d-46e8-845d-2b063aa6e8b1 --><!-- end item 94908287-4a7d-4a66-9192-af3302c03f37 --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What are the key drug interactions with warfarin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8a94a581-1161-42e8-9234-1dcc857cc2e6 --><!-- begin field d12694b1-0459-4596-b645-bcb7a5db0ab4 --><p><strong>If prescribing a drug that may interact, check the person’s international normalized ratio (INR) 3–5 days after starting treatment with the new drug.</strong></p><ul><li><strong>The following interactions may <em>enhance </em>the effect of warfarin</strong> and are likely to need close monitoring and clinical intervention, especially when initiating, changing, and stopping concurrent treatment.<ul><li><strong>Alcohol </strong>— the person should avoid binge drinking. Heavy drinkers or people with liver disease should avoid alcohol or should not take warfarin.</li><li><strong>Amiodarone </strong>— during the loading phase, check the INR once a week and adjust the dose according to the INR. When the loading phase has been completed, check the INR every 2–4 weeks for 1–2 months. Similarly, when stopping amiodarone, the INR should be checked frequently and the dose adjusted as needed. The interaction between warfarin and amiodarone persists for a month or more after amiodarone is withdrawn.</li><li><strong>Antibiotics </strong>— measure the INR 4–7 days after any antibiotic has been started. It is difficult to predict if the INR will increase or decrease (this will also depend on how ill the person is). For example:<ul><li><strong>Co-trimoxazole </strong>— consider whether trimethoprim can be used instead, or reduce warfarin dose.</li><li><strong>Metronidazole, erythromycin, and clarithromycin </strong>— reduce the warfarin dose as necessary.</li></ul></li><li><strong>Antidepressants </strong>— selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) should be avoided where possible because of their antiplatelet effect. Some tricyclic antidepressants (TCAs) and mirtazapine should also be avoided due to an enhanced anticoagulant effect. Consider offering trazodone instead.</li><li><strong>Aspirin or aspirin-containing products (for example, cold and influenza preparations, and topical salicylates) </strong>—<strong> </strong>avoid concurrent use<strong> </strong>unless clinically indicated.</li><li><strong>Azoles (in particular fluconazole, miconazole, and voriconazole) </strong>— measure the INR 4–7 days after an oral azole has been started, and adjust the dose based on the INR. Monitoring is also recommended in people using intravaginal or topical miconazole.<ul><li>If miconazole and warfarin are used concurrently, the anticoagulant effect should be carefully monitored and, if necessary, the dose of warfarin reduced.</li></ul></li><li><strong>Cranberry juice or cranberry-containing products </strong>— advise the person to avoid concurrent use; INRs greater than 8 have occurred.</li><li><strong>Clopidogrel or dipyridamole </strong>— concurrent use should be avoided unless clinically indicated.</li><li><strong>Corticosteroids </strong>— recheck the INR 4–7 days after starting an oral corticosteroid, and adjust the dose of warfarin as needed based on the INR.</li><li><strong>Direct-acting </strong><strong>antiviral medications for treatment of chronic hepatitis C</strong> — monitor INR closely, and adjust warfarin treatment if necessary. Changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of warfarin because of possible changes in liver function during treatment. Direct-acting antiviral medications include boceprevir (Victrelis®), daclatasvir (Daklinza®), dasabuvir (Exviera®), ombitasvir/paritaprevir/ritonavir (Viekirax®), sofosbuvir (Sovaldi®), ledipasvir with sofosbuvir (Harvoni®), and simeprevir (Olysio®). </li><li><strong>Fibrates </strong>— avoid concurrent use if possible, or reduce the warfarin dose as necessary.</li><li><strong>Glucosamine </strong>— avoid concurrent use.</li><li><strong>Nonsteroidal anti-inflammatory drugs</strong> (NSAIDs) — avoid concurrent use, or reduce warfarin dose as necessary. If the person must<em> </em>take an oral NSAID, measure the INR 4–7 days after starting treatment. In addition, the person must be counselled on the signs of gastrointestinal bleeding. </li><li><strong>Tamoxifen </strong>— avoid concurrent use, or reduce warfarin dose as necessary. Measure the person's INR 1–2 weeks after starting treatment with tamoxifen.</li><li><strong>Thyroxine </strong>— reduce warfarin dose as necessary. Consider weekly monitoring whilst the thyroxine dose is being titrated.</li></ul></li><li><strong>The following interactions may <em>reduce </em>the effect of warfarin </strong>and are likely to need close monitoring and clinical intervention, especially when initiating, changing, and stopping concurrent treatment.<br><ul><li><strong>St John's Wort </strong>— stop St John's Wort, monitor the INR, and adjust warfarin dose as necessary. St John's wort can cause a moderate clinical reduction in the anticoagulant effect.</li><li><strong>Griseofulvin </strong>— increase warfarin dose as necessary.</li><li><strong>Rifampicin </strong>— increase warfarin dose as necessary.</li><li><strong>Carbamazepine </strong>— increase warfarin dose as necessary.</li><li><strong>Phenobarbital or primidone </strong>— a reduced effect may be seen within 2–4 days (maximum effect by about 3 weeks) after starting phenobarbital and persisting for up to 6 weeks after phenobarbital is stopped. Monitor INR until stable. Increase warfarin dose as necessary.</li><li><strong>Phenytoin </strong>— increase warfarin dose as necessary. After stopping phenytoin, the INR may continue to be affected for up to 6 weeks.</li><li><strong>Vitamin K-containing vitamin complexes,</strong> including some enteral feeds (containing vitamin K), mineral supplements, and green vegetables (as well as over-the-counter chilblain products) — the warfarin dose should be increased, or the intake of vitamin K reduced. Vitamin K-rich diets should not be changed without at the same time reducing the warfarin dose, because excessive anticoagulation and bleeding may occur.</li></ul></li><li><strong>In addition, it is also prudent to monitor the INR when warfarin is used concurrently with the following drugs, especially in older people, as interactions have been documented:</strong><ul><li>Allopurinol.</li><li>Azathioprine.</li><li>Grapefruit juice (it may be easier to completely avoid this).</li><li>Influenza vaccine.</li><li>Methylphenidate.</li><li>Orlistat (may reduce the absorption of vitamin K).</li><li>Paracetamol or paracetamol-containing products (particularly if prolonged regular use).</li><li>Proton pump inhibitors.</li><li>Quinolone antibiotics.</li><li>Statins (particularly fluvastatin or rosuvastatin; not pravastatin).</li><li>Stopping smoking (it takes about 1 week for enzyme induction due to smoking to wear off).</li><li>Zafirlukast.</li></ul></li><li>See the <a href="http://www.medicines.org.uk/emc" data-hyperlink-id="bf6bda62-14be-48b6-a3bd-a98d000d45b6">electronic Medicines Compendium</a> (eMC) or the <a href="https://bnf.nice.org.uk/" data-hyperlink-id="f811dbb2-4c9a-4436-be05-a98d000d462f">British National Formulary</a> (BNF) for other possible drug interactions with warfarin.</li></ul><!-- end field d12694b1-0459-4596-b645-bcb7a5db0ab4 --><!-- end item 8a94a581-1161-42e8-9234-1dcc857cc2e6 --></div><section aria-labelledby="basis-for-recommendation-96c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-96c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 96c5ed08-82cf-4337-aab6-b4cc9224731b --><!-- begin field 03b2cf48-0ca8-4880-a9b0-67d4b4c5a976 --><p>These recommendations are based on the British Committee for Standards in Haematology (BCSH) <em>Guidelines on oral anticoagulation with warfarin - fourth edition</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>], the Summary of Product Characteristics (SPC) for warfarin sodium 1 mg/1 ml oral suspension [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020f</a>], the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety updates <em>Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016b</a>] and <em>Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2017</a>], and information in a medical textbook [<a class="bibliography-reference internal-reference" href="../../references/index.html">Preston, 2015</a>].</p><!-- end field 03b2cf48-0ca8-4880-a9b0-67d4b4c5a976 --><!-- end item 96c5ed08-82cf-4337-aab6-b4cc9224731b --></div></section></section><section aria-labelledby="surgery-dental-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="surgery-dental-treatment">Should warfarin be stopped before planned surgery or dental treatment?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d5f23a43-6c3a-499e-b381-af942d8adf6e --><!-- begin field b8cba69b-0e40-45d7-9451-6d919bc41dbb --><ul><li><strong>If the person needs to have surgery or any other invasive procedure, they may need to temporarily stop taking warfarin.</strong></li><li><strong>Minor surgical procedures with low risk of bleeding</strong> can be performed in general with an international normalized ratio (INR) of less than 2.5. However, local recommendations should be considered. </li><li><strong>For surgery or other surgical procedures where there is a risk of severe bleeding: </strong><ul><li>Warfarin should be stopped 3–5 days prior to the surgery or procedure.</li><li>Where it is necessary to continue anticoagulation, for example with life-threatening thromboembolism, the INR should be reduced to less than 2.5 and heparin therapy should be started.</li><li>If surgery is required and warfarin cannot be stopped 3 days beforehand, anticoagulation should be reversed with low-dose vitamin K.</li><li>The timing for re-instating warfarin treatment depends on the risk of post-operative haemorrhage. In most instances, warfarin treatment can be re-started as soon as the person has an oral intake.</li></ul></li><li><strong>For dental procedures:</strong><ul><li>In most cases, warfarin need not be stopped before routine dental surgery, for example tooth extraction.</li><li>It is recommended that the INR is checked 72 hours before dental surgery. The risk of significant bleeding in people with a stable INR within the range of 2–4 is very small, but the risk of thrombosis may be increased if oral anticoagulants are temporarily discontinued.</li></ul></li></ul><!-- end field b8cba69b-0e40-45d7-9451-6d919bc41dbb --><!-- end item d5f23a43-6c3a-499e-b381-af942d8adf6e --></div><section aria-labelledby="basis-for-recommendation-342" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-342">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3428c4b9-cc6d-4270-aeac-d80610e757f2 --><!-- begin field 020068bc-36fb-42ef-b1d7-c154507dade7 --><p>These recommendations are based on the British Society for Haematology (BSH) guideline <em>Peri-operative management of anticoagulation and antiplatelet therapy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BSH, 2016</a>] and the Summary of Product Characteristics (SPC) for warfarin sodium 1 mg/1 ml oral suspension [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020f</a>].</p><!-- end field 020068bc-36fb-42ef-b1d7-c154507dade7 --><!-- end item 3428c4b9-cc6d-4270-aeac-d80610e757f2 --></div></section></section><section aria-labelledby="monitoring" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring">How should I monitor someone taking warfarin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e63703d5-930f-4585-8412-2bcafd54908d --><!-- begin field c501527a-3aa9-4dd9-b208-da65c798d50e --><ul><li><strong>The anticoagulant effect of warfarin is measured as the international normalized ratio (INR).</strong><ul><li>The INR calculation is based on the ratio between the prothrombin times of the test and control samples.</li><li>The INR is most accurately measured in venous blood samples, but many anticoagulation clinics use capillary blood samples because these are more convenient to obtain.</li><li>Intravenous drug users and people with hepatitis B, hepatitis C, or HIV, may be referred to a specialist clinic. Capillary blood sampling in these populations may cause risk of transmission, and venous access is often difficult. Arrangements for monitoring the INR in such cases may vary with locality.</li></ul></li><li><strong>Generally, the INR should be measured:</strong><ul><li><strong>Daily, or on alternate days,</strong> until it is within the therapeutic range (usually between 2–3, ideally 2.5) on two consecutive occasions.<ul><li>Although the INR may be measured each day after starting warfarin, a meaningful INR can only be obtained 3–4 days after starting treatment.</li></ul></li><li><strong>Then, twice weekly </strong>for 1–2 weeks, followed by weekly measurements until at least two INR measurements are within the therapeutic range.</li><li><strong>Thereafter, </strong>depending on the stability of the INR, at longer intervals (for example, up to every 12 weeks) if agreed locally. Once a stable warfarin dose that controls the INR has been established, changes in dose are seldom required.</li></ul></li><li><strong>More frequent routine monitoring (for example every 1–2 weeks) of the INR is recommended for people:</strong><ul><li>At an increased risk of overcoagulation, for example people with severe hypertension, liver disease (including alcoholic liver disease), or renal failure.</li><li>At increased risk of bleeding, for example people on high-intensity anticoagulation (INR more than 4) and those aged 65 years and older.</li><li>For whom adherence to treatment may be difficult.</li></ul></li><li><strong>Reassess anticoagulation for a person with poor anticoagulation control,</strong> indicated by any of the following:<ul><li>Two INR values higher than 5, or one INR value higher than 8 within the past 6 months. </li><li>Two INR values less than 1.5 within the past 6 months.</li><li>Time in therapeutic range (TTR) is less than 65%. </li></ul></li><li><strong>The person on warfarin should:</strong><ul><li>Have all their results recorded in their 'Yellow book', with their dose instructions and their next appointment time.</li><li>Be aware of the reasons for anticoagulation, their target INR, and the duration of their treatment.</li><li>Receive appropriate <a class="topic-reference internal-reference" href="index.html#advice-to-patients">information and advice</a> on warfarin treatment.</li></ul></li><li><strong>Warfarin metabolism can be affected by:</strong><ul><li>Thyroid status — people with hypothyroidism or hyperthyroidism should be closely monitored on starting warfarin treatment.</li><li>Genetic variability — if the person or a family member is known to have polymorphisms of CYP2CP or VKORC1, extra care is warranted.</li></ul></li></ul><!-- end field c501527a-3aa9-4dd9-b208-da65c798d50e --><!-- end item e63703d5-930f-4585-8412-2bcafd54908d --></div><section aria-labelledby="basis-for-recommendation-96c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-96c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 96cb63e6-aded-4780-a4cf-c7a39bff5906 --><!-- begin field 8a478bf4-7753-4a9e-8025-c0575b62b8ed --><p>These recommendations are largely based on the British Committee for Standards in Haematology (BCSH) <em>Guidelines on oral anticoagulation with warfarin - fourth edition</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>].</p><!-- end field 8a478bf4-7753-4a9e-8025-c0575b62b8ed --><!-- end item 96cb63e6-aded-4780-a4cf-c7a39bff5906 --></div></section></section><section aria-labelledby="monitoring-during-the-covid-19-pandemic" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring-during-the-covid-19-pandemic">How should I monitor a person taking warfarin during the COVID-19 pandemic?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8986cc4c-b156-4bf6-9700-0032f2f63141 --><!-- begin field d6c3b2b3-625a-41f0-8df8-acb401762b5d --><ul><li><strong>When monitoring a person taking warfarin during the COVID-19 pandemic, remember that:</strong><ul><li>Acute illness (including COVID-19 infection) may exaggerate the effect of warfarin and necessitate a dose reduction.</li><li>Continued international normalized ratio (INR) monitoring is important in people taking warfarin if they have suspected or confirmed COVID-19 infection, so they can be clinically managed at an early stage to reduce the risk of bleeding.</li><li>Warfarin may <a class="topic-reference internal-reference" href="index.html#drug-interactions">interact</a> with other medicines (including antibacterials and antivirals). Follow the advice in the manufacturer's Summary of Product Characteristics (SPC), available on the <a href="http://www.medicines.org.uk/emc" data-hyperlink-id="bf6bda62-14be-48b6-a3bd-a98d000d45b6">electronic Medicines Compendium</a> (eMC) website, to minimize the risk of potential interactions.</li><li>If switching from warfarin to a direct-acting oral anticoagulant (DOAC), stop warfarin before starting the DOAC, to reduce the risk of over-anticoagulation and bleeding. See the sections on switching to <a class="topic-reference internal-reference" href="../apixaban/index.html#switching-anticoagulants">Apixaban</a>, <a class="topic-reference internal-reference" href="../dabigatran/index.html#switching-anticoagulants">Dabigatran</a>, <a class="topic-reference internal-reference" href="../edoxaban/index.html#switching-anticoagulants">Edoxaban</a>, and <a class="topic-reference internal-reference" href="../rivaroxaban/index.html#switching-anticoagulants">Rivaroxaban</a> for more information.</li></ul></li><li><strong>Remind the person to:</strong><ul><li>Carefully follow the instructions for the use of warfarin, including those in the <a href="https://www.medicines.org.uk/emc/product/4442#gref" data-hyperlink-id="82f29d9b-f0ad-43d6-bbc4-acb401828a52">patient information leaflet</a>.</li><li>Notify the GP or healthcare team if they:<ul><li>Have symptoms of, or confirmed, COVID-19 infection.</li><li>Are otherwise unwell with sickness or diarrhoea, or have lost their appetite.</li><li>Have changed their diet, smoking habits, or alcohol consumption.</li><li>Are taking any new medicines or supplements.</li><li>Are unable to attend their next scheduled blood test for any reason.</li></ul></li></ul></li></ul><!-- end field d6c3b2b3-625a-41f0-8df8-acb401762b5d --><!-- end item 8986cc4c-b156-4bf6-9700-0032f2f63141 --></div><section aria-labelledby="basis-for-recommendation-8d9" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-8d9">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8d9d23ac-508a-4018-b9fb-686de55368c9 --><!-- begin field 74db2498-e1ab-4510-98cd-acb401762b5d --><p>This recommendation is based on the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020b</a>] and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><ul><li>Warfarin levels can be affected by diet, alcohol, acute illness, and other medications, including over-the-counter drugs, vitamins, food supplements, and herbal and homeopathic remedies [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field 74db2498-e1ab-4510-98cd-acb401762b5d --><!-- end item 8d9d23ac-508a-4018-b9fb-686de55368c9 --></div></section></section><section aria-labelledby="target-inrs" class="ChapterBody-module--wrapper--2HCfk "><h3 id="target-inrs">What is target international normalized ratio (INR) for warfarin treatment?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 88e9237c-432e-4c2e-bddd-f227f5a716e0 --><!-- begin field 53bd1bf1-d1dd-4697-ba7b-490ab98b7cb2 --><ul><li><strong>The maintenance dose of warfarin depends on the international normalized ratio (INR) during monitoring.</strong><ul><li>The average daily maintenance dose of warfarin is usually around 5 mg taken at the <em>same time </em>every day. However, there is wide variation from person-to-person and the daily dose may lie between 1–15 mg for some people.</li><li>An INR that is within 0.5 units of the target value is generally satisfactory; larger deviations require dosage adjustment. Target values (rather than ranges) are now recommended.</li></ul></li><li><strong>A target INR of 2.5 is recommended for:</strong><ul><li style="line-height: 24px;">Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), including those associated with antiphospholipid syndrome or for recurrence in people no longer receiving warfarin treatment.</li><li>Atrial fibrillation.</li><li>Cardioversion (higher target values, such as an INR of 3, can be used for up to 4 weeks before the procedure to avoid cancellations due to low INR).</li><li>Mitral stenosis or regurgitation with atrial fibrillation, history of systemic embolism, left atrial thrombus, or enlarged left atrium.</li><li>Bioprosthesis in the mitral position.</li><li>Bioprosthetic valve and history of systemic embolism.</li><li>Bioprosthetic valve and left atrial thrombus at surgery.</li><li>Bioprosthetic valves and other prothrombotic risk factors, such as atrial fibrillation and low ventricular ejection fraction.</li><li>Acute arterial embolism leading to embolectomy.</li><li>Dilated cardiomyopathy.</li><li>Post myocardial infarction.</li></ul></li><li><strong>A target INR of 3.5 is recommended for:</strong><ul><li>Recurrent DVT or PE in people currently receiving anticoagulation and with an INR above 2.</li></ul></li><li><strong>For mechanical prosthetic heart valves:</strong><ul><li>The recommended target INR depends on the type and location of the valve, and patient-related risk factors. Increasing the INR target or adding an antiplatelet drug should be considered if an embolic event occurs whilst the person is anticoagulated at the target INR.</li><li>See Table 1 for the recommended target INRs for mechanical valves.</li></ul></li></ul><p style="margin-top: 0px; margin-bottom: 10px;"><strong>Table 1.</strong> Recommended target international normalized ratios (INRs) for mechanical valves.</p><table data-table-id="70500865-0e47-4d5f-bd08-acce00f75953"><thead><tr><th colspan="1">Prosthesis thrombogenicity</th><th colspan="1">INR target (no patient risk factors)</th><th colspan="1"><strong>INR target (patient-related risk factors)*</strong></th></tr></thead><tbody><tr><td colspan="1">Low</td><td colspan="1">2.5</td><td colspan="1">3.0</td></tr><tr><td colspan="1">Medium</td><td colspan="1">3.0</td><td colspan="1">3.5</td></tr><tr><td colspan="1">High</td><td colspan="1">3.5</td><td colspan="1">3.5†</td></tr><tr><td colspan="3">*Patient-related risk factors for thrombosis include mitral, tricuspid, or pulmonary position; previous arterial thromboembolism; atrial fibrillation; left atrium diameter >50 mm; mitral stenosis of any degree; left ventricular ejection fraction <35%; left atrial dense spontaneous echo contrast</td></tr><tr><td colspan="3">†4.0 in <em>Guideline for the management of patients with valvular heart disease </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Nishimura, 2014</a>]</td></tr><tr><td colspan="3"><strong>Data from:</strong> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>]</td></tr></tbody></table><p> </p><!-- end field 53bd1bf1-d1dd-4697-ba7b-490ab98b7cb2 --><!-- end item 88e9237c-432e-4c2e-bddd-f227f5a716e0 --></div><section aria-labelledby="basis-for-recommendation-935" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-935">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 935c125d-f599-42dc-813c-843b7c6ce11a --><!-- begin field ee8a2414-e016-4f00-a6f2-68facdfe848f --><p>These recommendations are based on the British Committee for Standards in Haematology (BCSH) <em>Guidelines on oral anticoagulation with warfarin - fourth edition</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>] and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field ee8a2414-e016-4f00-a6f2-68facdfe848f --><!-- end item 935c125d-f599-42dc-813c-843b7c6ce11a --></div></section></section><section aria-labelledby="inr-not-in-range" class="ChapterBody-module--wrapper--2HCfk "><h3 id="inr-not-in-range">How should I manage a person if their INR is not in the therapeutic range?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 306745a9-3431-41ae-b621-b01c84381b48 --><!-- begin field 5e851962-7b5c-4424-8ccb-4bed7b71fa61 --><ul><li><strong>If the international normalized ratio (INR) is outside the therapeutic range, </strong>ask the person about any changes in order to find a cause of the out-of-range result. For example, ask about:<ul><li>Adherence to warfarin treatment, for example if they have missed any doses or taken too much.</li><li>Use of other <a class="topic-reference internal-reference" href="index.html#drug-interactions">medications</a>, including over-the-counter products, vitamins, and herbal or homeopathic remedies.</li><li>Use of alcohol or illicit drugs.</li><li>Food and drink intake (for example green vegetables and cranberry juice).</li><li>Their general health:<ul><li>Weight loss, acute illness (such as gastroenteritis), and smoking cessation can increase the effect of warfarin.</li><li>Weight gain, diarrhoea, and vomiting can reduce the effect of warfarin.</li></ul></li></ul></li><li><strong>If the person has major bleeding,</strong> stop warfarin, and refer urgently for intravenous treatment with phytomenadione (vitamin K<sub>1</sub>) and dried prothrombin complex concentrate (factors II, VII, IX, and X), or fresh frozen plasma if dried prothrombin complex is unavailable.</li><li><strong>If the INR is high and is:</strong><ul><li><strong>Greater than 8 with minor bleeding </strong>— stop warfarin and give phytomenadione by slow intravenous injection. The dose of phytomenadione may be repeated after 24 hours if the INR is still too high.<ul><li>Restart warfarin when the INR is less than 5.</li></ul></li><li><strong>Greater than 8 with no bleeding </strong>— stop warfarin and give phytomenadione by mouth using the intravenous preparation orally (off-label use). The dose of phytomenadione may be repeated after 24 hours if the INR is still too high.<ul><li>Restart warfarin when the INR is less than 5.</li></ul></li><li><strong>Between 5–8 with minor bleeding </strong>— stop warfarin and give phytomenadione by slow intravenous injection.<ul><li>Restart warfarin when the INR is less than 5.</li></ul></li><li><strong>Between 5–8 with no bleeding </strong>— withhold 1 or 2 doses of warfarin and reduce subsequent maintenance dose.</li></ul></li><li><strong>If there is unexpected bleeding at therapeutic levels </strong>— always investigate possibility of underlying cause, such as unsuspected renal or gastrointestinal tract pathology.</li></ul><!-- end field 5e851962-7b5c-4424-8ccb-4bed7b71fa61 --><!-- end item 306745a9-3431-41ae-b621-b01c84381b48 --></div><section aria-labelledby="basis-for-recommendation-33a" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-33a">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 33a27165-2533-46d0-a48d-b1acb0f15dbc --><!-- begin field 26ddda53-d9c5-4fe2-9ade-9be53e37cc99 --><p>These recommendations are based on the British Committee for Standards in Haematology (BCSH) <em>Guidelines on oral anticoagulation with warfarin - fourth edition</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Keeling, 2011</a>] and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field 26ddda53-d9c5-4fe2-9ade-9be53e37cc99 --><!-- end item 33a27165-2533-46d0-a48d-b1acb0f15dbc --></div></section></section><section aria-labelledby="advice-to-patients" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advice-to-patients">What advice should I give to a person receiving warfarin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3ac22dc0-2ae4-451a-b8c2-fa472833394c --><!-- begin field db78b4c0-1bcb-4a59-bab5-632c9fe22a4f --><ul><li><strong>Advise the person taking warfarin that:</strong><ul><li>It is very important to have their blood tested regularly to check their international normalized ratio (INR), at intervals agreed with the anticoagulant clinic staff.<ul><li>They should always take their anticoagulant treatment booklet ('Yellow book') when they go to the warfarin clinic to have their INR checked.</li><li>The 'Yellow book' includes advice for people taking anticoagulants, an alert card (which the person should carry at all times), and a section for recording the INR readings.</li></ul></li><li>They should take their warfarin at the <em>same time </em>each day.</li><li>They should not miss doses or take additional doses, without advice from a healthcare professional.<ul><li>They must inform anticoagulant clinic staff if they think they have taken too much warfarin or have missed any doses.</li><li>If a dose is accidentally missed, they should continue with the regimen as prescribed, and <em>never </em>take a double dose (unless specifically advised).</li></ul></li><li>Warfarin levels can be affected by diet, alcohol, acute illness, and other medications, including over-the-counter drugs, vitamins, food supplements, and herbal and homeopathic remedies. They should:<ul><li>Seek medical advice before undertaking any major changes in diet, especially if their diet is rich in vitamin K (such as broccoli, kale, or spinach) — this can potentially affect control of anticoagulation.</li><li>Limit alcohol intake to a maximum of one or two drinks a day, and never binge drink.</li><li>Inform the anticoagulant clinic staff and other healthcare professional (their GP, dentist, pharmacist, and/or medical or nursing staff) of changes to their lifestyle, for example if they start, stop, or change the dose of other medicines.</li></ul></li><li>They should seek immediate medical advice if:<br><ul><li>Spontaneous bleeding occurs whilst on warfarin and the bleeding does not stop, or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, coughing up blood, a subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li>They get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li><li>They experience difficulty breathing, increased breathing rate, or chest pain (which could be symptoms of pulmonary embolism).</li></ul></li><li>They should seek medical advice if they experience other <a class="topic-reference internal-reference" href="index.html#adverse-effects">adverse effects</a> of warfarin. </li><li>They may have to stop warfarin treatment temporarily for certain <a class="topic-reference internal-reference" href="index.html#surgery-dental-treatment">surgical and dental treatments</a>.</li><li>They should:<br><ul><li>Expect to bruise more easily.</li><li>Take extra care when brushing teeth or shaving and consider using a soft toothbrush and an electric razor.</li></ul></li></ul></li><li><strong>For women of childbearing potential, advise that:</strong><ul><li>They should use effective contraception during treatment because warfarin is a known teratogen.<ul><li>If she becomes pregnant (or is planning a pregnancy), she needs to stop taking warfarin and start using low molecular weight heparin.</li></ul></li></ul></li></ul><!-- end field db78b4c0-1bcb-4a59-bab5-632c9fe22a4f --><!-- end item 3ac22dc0-2ae4-451a-b8c2-fa472833394c --></div><section aria-labelledby="basis-for-recommendation-08c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-08c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 08c43e45-e397-4af3-be9f-2a028debb3fc --><!-- begin field 4f41b145-22ac-4754-b093-e5cf0ebc5d56 --><p>These recommendations are based on expert opinion in the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Antithrombotics: indications and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>], the Summary of Product Characteristics (SPC) for warfarin sodium 1 mg/1 ml oral suspension [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020f</a>], and the British National Formulary (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field 4f41b145-22ac-4754-b093-e5cf0ebc5d56 --><!-- end item 08c43e45-e397-4af3-be9f-2a028debb3fc --></div></section></section><section aria-labelledby="self-testing-self-management" class="ChapterBody-module--wrapper--2HCfk "><h3 id="self-testing-self-management">What is self-testing and self-management of warfarin?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cbcdb54c-7887-4336-8b8f-108ba8eff230 --><!-- begin field c660ac2c-7e76-4249-aa54-e8187cf29bf9 --><ul><li><strong>Self-testing </strong>is where a person tests their own international normalized ratio (INR) but contacts a healthcare professional for dose adjustment.</li><li><strong>Self-management </strong>is where the person tests their own INR and also adjusts the dose of warfarin themselves (based on an individualized algorithm).</li><li><strong>The availability of training and support for self-testing or self-management varies across the UK.</strong><ul><li>Training and on-going review and support are best managed through specialist anticoagulant services (based in primary or secondary care).</li><li>People should only consider purchasing a self-testing device, such as the CoaguChek® INRange, after discussing the following with their GP or with the anticoagulant clinic staff:<ul><li>Whether self-testing or self-management services (such as <a class="topic-reference internal-reference" href="index.html#training-for-self-testing-self-management">training and support</a>, and specialist review) are available in their area.</li><li>Their <a class="topic-reference internal-reference" href="index.html#suitability-for-self-testing-self-management">suitability</a> for self-testing or self-management.</li></ul></li><li>Warfarin self-testing devices are not available on the NHS; however, some test strips and lancets are available on prescription.</li></ul></li><li><strong>For selected and successfully trained people, </strong>self-testing or self-management are as effective and safe as usual care for long-term oral anticoagulation treatment and can improve the quality of oral anticoagulation treatment in this group of people. In the UK, however, self-testing is unlikely to be more cost-effective than usual care, because of the increased frequency of testing and subsequent cost of test strips.</li></ul><!-- end field c660ac2c-7e76-4249-aa54-e8187cf29bf9 --><!-- end item cbcdb54c-7887-4336-8b8f-108ba8eff230 --></div><section aria-labelledby="suitability-for-self-testing-self-management" class="ChapterBody-module--wrapper--2HCfk "><h4 id="suitability-for-self-testing-self-management">Who is suitable for warfarin self-testing or self-management?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 701b54d1-3b43-43c3-aaf0-3d8dfcb1001f --><!-- begin field 6c0a1060-1383-4bc0-aa54-acb10126a310 --><ul><li><strong>People who require long-term anticoagulation can be considered for warfarin self-testing or self-management.</strong><ul><li>Those who may benefit most are those who are frequently away from home, are in employment or in education, or find it difficult to travel to clinics.</li><li>Previous stability of international normalized ratio (INR) is not a prerequisite to home testing, as people with an unstable INR may benefit from the possibility of increased frequency of testing.</li></ul></li><li><strong>The following criteria should be met before self-testing is considered:</strong><ul><li>The person is both physically and cognitively able to perform the self-monitoring test, or a designated carer is able to do so.</li><li>An adequate supportive educational programme is in place to train the person and/or carers.</li><li>The person's ability to self-test or self-manage can be regularly reviewed.</li><li>The person will have access to appropriately trained healthcare professionals for ongoing advice and support (including if they plan to travel abroad).</li></ul></li><li><strong>The following additional criterion should also be met before self-managing is considered:</strong><ul><li>The person is cognitively able to follow an individualized algorithm to adjust their own dose of warfarin, or a designated carer is able to do so.</li><li>The person is sufficiently motivated to self-manage.</li></ul></li><li><strong>The following people are <em>not </em>suitable for self-testing or self-management:</strong><ul><li>Those who fail to attend clinic appointments (unless work, school, or access make it hard to attend clinic, in which case self-testing or self-managing may be helpful).</li><li>Those who do not adhere to their dosage instructions.</li><li>Those who do not wish to do so.</li></ul></li></ul><!-- end field 6c0a1060-1383-4bc0-aa54-acb10126a310 --><!-- end item 701b54d1-3b43-43c3-aaf0-3d8dfcb1001f --></div></section><section aria-labelledby="training-for-self-testing-self-management" class="ChapterBody-module--wrapper--2HCfk "><h4 id="training-for-self-testing-self-management">What training and support is needed for people who are self-testing or self-managing?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a726438b-fc93-4b5c-9cc7-328b57672e2a --><!-- begin field 88ef04d3-c518-4bb5-a813-acb10126a310 --><ul><li><strong>The person must:</strong><ul><li>Give informed consent to self-testing or self-management, including agreement to record results accurately and participate in a quality assurance scheme for the device.</li><li>If self-testing, understand who to contact with their international normalized ratio (INR) readings, and how they will be informed of their new warfarin dose.</li><li>If self-managing, be trained to adjust the dose of warfarin correctly based on the INR result, using an individualized patient algorithm.</li></ul></li><li><strong>Training should include: </strong><ul><li>The theoretical aspects of anticoagulation management.</li><li>How to monitor and record results, and the frequency of coagulation monitoring.</li><li>Problems with monitoring (identifying possible sources of error).</li><li>Interaction between anticoagulants and other medications. </li><li>The influences of nutrition, alcohol, illness, and travel.</li><li>How to recognize and treat complications.</li><li>The target INR for their condition and the importance of maintaining the INR within 0.5 of their target.</li></ul></li><li><strong>Once training has been completed, the person must:</strong><ul><li>Be reviewed at least every 6 months by the responsible clinician.</li><li>Have access to an appropriately trained healthcare professional for advice when needed (by telephone or in person).</li><li>Participate in a scheme to check the device is working correctly:<ul><li>Either by participating in a formal external quality assurance programme, such as <a href="http://www.ukneqasbc.org/content/PageServer.asp?S=102654210&C=1252&ID=29" data-hyperlink-id="479c6610-86c8-4a20-b52d-a8f7014ec1e5">UKNEQAS</a>.</li><li>Or by regularly attending clinic (such as every 6 months) to take a venous sample for comparison, or to use the clinic point of care device for comparison.</li></ul></li><li>Check that each batch of test strips is working correctly.<ul><li>Some strips come with a built-in internal quality assurance facility.</li><li>For others, the manufacturers supply samples of known INR to be used for quality assurance testing.</li></ul></li></ul></li></ul><!-- end field 88ef04d3-c518-4bb5-a813-acb10126a310 --><!-- end item a726438b-fc93-4b5c-9cc7-328b57672e2a --></div></section><section aria-labelledby="basis-for-recommendation-571" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-571">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 57130283-b3ad-4238-9534-7caa48d10e8b --><!-- begin field 4b52cc6a-7481-4711-ac89-129d92725183 --><h5>Information on self-testing and self-management</h5><ul><li>The information on self-testing and self-management is largely based on <em>Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Jennings, 2014</a>].</li><li>The National Institute for Health and Care Excellence (NICE) guideline<em> Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) </em>provides evidence-based recommendations on the CoaguChek® XS system for self-monitoring coagulation status. The CoaguChek® XS system was replaced with an updated version, the CoaguChek® INRange, and NICE published a <a href="https://www.nice.org.uk/guidance/dg14/resources/summary-of-the-main-changes-to-the-coaguchek-xs-system-pdf-4844245789" data-hyperlink-id="b7d8dfb4-7f0c-42e1-8a60-acb10134e512">technical supplement</a> to highlight the major features of the updated version [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2017</a>].</li></ul><h5 class="MsoNormal">Safety and efficacy of self-testing and self-management</h5><ul><li>These recommendations are based on evidence from a Cochrane systematic review [<a class="bibliography-reference internal-reference" href="../../references/index.html">Heneghan, 2016</a>] and a systematic review and economic modelling [<a class="bibliography-reference internal-reference" href="../../references/index.html">Connock, 2007</a>].<ul><li>The Cochrane systematic review identified 28 randomized controlled trials (n = 8950) that evaluated the effects on thrombotic events, major haemorrhages, and all-cause mortality of self-monitoring or self-management of oral anticoagulant treatment compared with standard monitoring. Low-to moderate-quality evidence showed that [<a class="bibliography-reference internal-reference" href="../../references/index.html">Heneghan, 2016</a>]:<ul><li>Thrombotic events were reduced for those self-monitoring or self-managing oral anticoagulation treatment.</li><li>A reduction in all-cause mortality was observed in trials of self-management but not in self-monitoring, with no effects on major haemorrhage.</li><li>For selected and successfully trained people, self-monitoring is effective and safe for long-term oral anticoagulation treatment.</li></ul></li><li>The systematic review and economic modelling identified 16 randomized and eight non-randomized trials and examined the clinical effectiveness and cost-effectiveness of self-testing and self-management of oral anticoagulation treatment compared with clinic-based monitoring. The evidence showed that [<a class="bibliography-reference internal-reference" href="../../references/index.html">Connock, 2007</a>]:<ul><li>For selected and successfully trained people, self-monitoring is effective and safe for long-term oral anticoagulation treatment.</li><li>In general, patient self-management is unlikely to be more cost-effective than the current specialized anticoagulation clinics in the UK, but self-monitoring may enhance the quality of life for some people who are frequently away from home, who are in employment or education, or those who find it difficult to travel to clinics. </li></ul></li></ul></li></ul><h5>Suitability and training for self-testing and self-management</h5><ul><li>These recommendations are based on the British Society of Haematology (BSH) guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Jennings, 2014</a>] and on <em>Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ansell, 2005</a>].</li></ul><!-- end field 4b52cc6a-7481-4711-ac89-129d92725183 --><!-- end item 57130283-b3ad-4238-9534-7caa48d10e8b --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/anticoagulation-oral/management/warfarin/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>